RAD21 and leukemia: In a fourth cohort including 114 children and adolescents with therapy refractory leukemia and lymphoma (INFORM), no germline indels or missense variants affecting RAD21 were identified, suggesting no enrichment in the relapsed or therapy refractory patients.